Management of cognitive impairments in schizophrenia: The therapeutic role of 5-HT receptors

Schizophrenia Research: Recent Advances

Volumn , Issue , 2012, Pages 321-336

  Ohno, Yukihiro ^a   Tatara, Ayaka ^a   Shimizu, Saki ^a   Sasa, Masashi ^b  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Nagisa Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84877940765     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (85)

1. H. Y. Meltzer, Schizophrenia Bull. 17, 263 (1991).
2. S. Kapur and G. Remington, Ann. Rev. Med. 52, 503 (2001).
3. Y. Ohno, Cent. Nerv. Syst. Agents Med. Chem. 10, 148 (2010).
4. Y. Ohno, CNS Neurosci. Ther. 17, 58 (2011).
5. H. Y. Meltzer and S. M. Stahl, Schizophr Bull. 2, 19 (1976).
6. P. Seeman, Synapse. 1, 133 (1987).
7. Y. Ohno, K. Ishida-Tokuda, T. Ishibashi, H. Sakamoto, R. Tagashira, T. Horisawa, et al. Pol. J. Pharmacol. 49, 213 (1997).
8. H. Y. Meltzer, Z. Li, Y. Kaneda and J. Ichikawa, Prog. Neuro-Psychopharmacol Biol. Psychiat. 27, 1159 (2003).
9. A. Bleich, S. L. Brown, R. Kahn and H. M. van Praag, Schizophr Bull. 14, 297 (1988).
10. A. Breier, Schizophr Res. 14, 187 (1995).
11. M. Wood and C. Reavill, Expert. Opin. Investig. Drugs. 16, 771 (2007).
12. J. A. Lieberman, T. S. Stroup, J. P. McEvoy, M. S. Swartz, R. A. Rosenheck, D. O. Perkins, et al. N. Engl. J. Med. 353, 1209 (2005).
13. R. S. Keefe, R. M. Bilder, S. M. Davis, P. D. Harvey, B. W. Palmer, J. M. Gold, et al. Arch. Gen. Psychiatry. 64, 633 (2007).
14. M. Davidson, S. Galderisi, M. Weiser, N. Werbeloff, W. W. Fleischhacker, R. S. Keefe, et al. Am. J. Psychiatry. 166, 675 (2009).
15. M. V. King, C. A. Marsden and K. C. Fone, Trends Pharmacol. Sci. 29, 482 (2008).
16. J. Walstab, G. Rappold and B. Niesler, Pharmacol. Ther. 128, 146 (2010).
17. B. L. Roth, Ann. Clin. Psychiatry. 6, 67 (1994).
18. N. M. Barnes and T. Sharp, Neuropharmacology. 38, 1083 (1999).
19. T. J. Pucadyil, S. Kalipatnapu and A. Chattopadhyay, Cell. Mol. Neurobiol. 25, 553 (2005).
20. A. Hirose, M. Sasa, A. Akaike and S. Takaori, Neuropharmacology. 29, 93 (1990).
21. P. Van den Hooff and M. Galvan, Br. J. Pharmacol. 106, 893 (1992).
22. V. Hadrava, P. Blier, T. Dennis, C. Ortemann and de Montigny C. Neuropharmacology. 34, 1311 (1995).
23. JA agonist, on activities of the lateral septal nucleus neurons in cats., In "Serotonin in the Central Nervous System and Periphery." edited by Y. Takada and G, Curzon, pp. 159, Elsevier Science BV, Amsterdam (1995).
24. J. R. Raymond, Y. V. Muklin, T. W. Gettys, and M. N. Garnovskaya, Brit. J. Pharmacol. 127, 1751 (1999).
25. K. Tada, K. Kasamo, N. Ueda, T. Suzuki, T. Kojima, and K. Ishikawa, J. Pharmacol. Exp. Ther. 288, 843 (1999).
26. J. P. Feighner, and W. F. Boyer, Psychopathology. 22, 21 (1989).
27. R. W. Fuller, J. Clin. Psychiatry. 52, 52 (1991).
28. Y. Ohno, Tandospirone citrate, a new serotonergic anxiolytic agent: A potential use in Parkinson's disease. In "Mapping the Progress of Alzheimer's and Parkinson's Disease." edited by Y. Mizuno, A. Fisher and I. Hanin, pp. 423, Kluwer Academic/Plenum, New York (2002).
29. H. Kusserow, B. Davies, H. Hörtnagl, I. Voigt, T. Stroh, B. Bert, et al. Brain. Res. Mol. Brain Res. 129, 104 (2004).
30. E. Akimova, R. Lanzenberger and S. Kasper, Biol. Psychiatry. 66, 627 (2009).
31. T. Hashimoto, N. Nishino, H. Nakai and C. Tanaka, Life Sci. 48, 355 (1991).
32. E. V. Gurevich and J. N. Joyce, Biol. Psychiatry. 42, 529 (1997).
33. T. Sumiyoshi, M. Matsui, S. Nohara, I. Yamashita, M. Kurachi, C. Sumiyoshi, et al. Am. J. Psychiatry. 158, 1722 (2001).
34. T. Sumiyoshi, S. Park, K. Jayathilake, A. Roy, A. Ertugrul and H. Y. Meltzer, Schizophrenia Res. 95, 158 (2007).
35. H. Y. Meltzer and T. Sumiyoshi, Behav. Brain Res. 195, 98 (2008).
36. T. Sumiyoshi, V. Bubenikova-Valesova, J. Horacek and B. Bert, Adv. Ther. 25, 1037 (2008).
37. M. J. Millan, J. Pharmacol. Exp. Ther. 295, 853 (2000).
38. M. L. Wadenberg, K. A. Young, J. T. Richter and P. B. Hicks, Neuropharmacology. 38, 151 (1999).
39. E. P. Prinssen, F. C. Colpaert and W. Koek, Eur. J. Pharmacol. 453, 217 (2002).
40. T. Ishibashi and Y. Ohno, Biog. Amines 8, 329 (2004).
41. Y. Ohno, S. Shimizu, J. Imaki, S. Ishihara, N. Sofue, M. Sasa, et al. Neuropharmacology 55, 717 (2008).
42. Y. Ohno, S. Shimizu, J. Imaki, S. Ishihara, N. Sofue, M. Sasa, et al. Prog. Neuro-Psychopharmacol Biol. Psychiat. 32, 1302 (2008).
43. Y. Ohno, S. Shimizu and J. Imaki, J. Pharmacol. Sci. 109, 593 (2009).
44. S. Shimizu, A. Tatara, J. Imaki and Y. Ohno, Prog. Neuro-Psychopharmacol Biol. Psychiat. 34, 877 (2010).
45. P. Blier and N. M. Ward, Biol. Psychiatry. 53, 193 (2003).
46. I. Misane and S. O. Ögren, Brit. J. Pharmacol. 28, 253 (2003).
47. M. Lüttgen, E. Elvander, N. Madjid and S. O. Ögren, Neuropharmacology. 48, 830 (2005).
48. N. Madjid, E. E. Tottie, M. Lüttgen, B. Meister, J. Sandin, A. Kuzmin, et al. J. Pharmacol. Exp. Ther. 316, 581 (2006).
49. S. O. Ögren, T. M. Eriksson, E. Elvander-Tottie, C. D'Addario, J. C. Ekström, P. Svenningsson, et al. Behav. Brain Res. 195, 54 (2008).
50. T. Ishibashi, T. Horisawa, K. Tokuda, T. Ishiyama, M. Ogasa, R. Tagashira, et al. J. Pharmacol. Exp. Ther. 334, 171 (2010).
51. T. Ishiyama, K. Tokuda, T. Ishibashi, A. Ito, S. Toma and Y. Ohno, Eur. J. Pharmacol. 572, 160 (2007).
52. M. Nakamura, M. Ogasa, J. Guarino, D. Phillips, J. Severs, J. Cucchiaro, et al. J. Clin. Psychiatry. 70, 829 (2009).
53. M. R. Livesey, M. A. Cooper, T. Z. Deeb, J.E. Carland, J. Kozuska, T.G. Hales, et al. J. Biol. Chem. 283, 19301 (2008).
54. J. M. Barnes, B. Costall, J. Coughlan, A. M. Domeney, P.A. Gerrard, M.E. Kelly, et al. Pharmacol. Biochem. Behav. 35, 955 (1990).
55. H. Hodges, P. Sowinski, J. J. Turner and A. Fletcher, Psychopharmacology (Berl). 125, 146 (1996).
56. A. F. Arnsten, C. H. Lin, C. H. Van Dyck, and K.J. Stanhope, Neurobiol. Aging. 18, 21 (1997).
57. F. J. Gil-Bea, J. Dominguez, M. García-Alloza, B. Marcos, B. Lasheras and M.J. Ramirez, Neuropharmacology. 47, 225 (2004).
58. M. G. Giovannini, I. Ceccarelli, B. Molinari, M. Cecchi, J. Goldfarb and P. Blandina, J. Pharmacol. Exp. Ther. 285, 1219 (1998).
59. Z. J. Zhang, W. H. Kang, Q. Li, X. Y. Wang, S. M. Yao and A.Q. Ma, Schizophr. Res. 88, 102 (2006).
60. S. Akhondzadeh, N. Mohammadi, M. Noroozian, N. Karamghadiri, A. Ghoreishi, A.H. Jamshidi, et al. Schizophr. Res. 107, 206 (2009).
61. Y. Ohno, J. Imaki, Y. Mae, T. Takahashi and A. Tatara, Neuropharmacology. 60, 201 (2011).
62. G. P. Reynolds, S. L. Mason, A. Meldrum, S. De Keczer, H. Parnes, R. M. Eglen, et al. Br. J. Pharmacol. 114, 993 (1995).
63. D. J. Fontana, S. E. Daniels, E. H. Wong, R. D. Clark and R. M. Eglen, Neuropharmacology. 36, 689 (1997).
64. N. Galeotti, C. Ghelardini and A. Bartolini, J. Pharmacol. Exp. Ther. 286, 1115 (1998).
65. L. Lamirault and H. Simon, Neuropharmacology. 41, 844 (2001).
66. E. G. Mohler, S. Shacham and S. Noiman, Neuropharmacology. 53, 563 (2007).
67. S. Consolo, S. Arnaboldi, S. Giorgi, G. Russi and H. Ladinsky, Neuroreport. 5, 1230 (1994).
68. A. Siniscalchi, I. Badini, L. Beani and C. Bianchi, Neuroreport. 10, 547 (1999).
69. U. Bickmeyer, M. Heine, T. Manzke and D. W. Richter, Eur. J. Neurosci. 16, 209 (2002).
70. R. P. Ward and D. M. Dorsa, J. Comp. Neurol. 370, 405 (1996).
71. M. L. Woolley, C. A. Marsden and K. C. Fone, Curr. Drug Targets CNS Neurol. Disord. 3, 59 (2004).
72. B. Marcos, F. J. Gil-Bea, W. D. Hirst, M. García-Alloza and M. J. Ramirez, Eur. J. Neurosci. 24, 1299 (2006).
73. E. S. Mitchell, T. Sexton and J. F. Neumaier, Neuropsychopharmacology. 32, 1520 (2007).
74. M. L. Woolley, J. C. Bentley, A. J. Sleight, C. A. Marsden and K. C. Fone, Neuropharmacology. 41, 210 (2001).
75. M. L. Woolley, C. A. Marsden, A. J. Sleight, C. A. Marsden and K. C. Fone, Psychopharmacology (Berl). 170, 358 (2003).
76. M. V. King, A. J. Sleight, M. L. Woolley, I. A. Topham, C. A. Marsden and K. C. Fone, Neuropharmacology. 47, 195 (2004).
77. C. K. Lieben, A. Blokland, A. Sik, E. Sung, P. van Nieuwenhuizen and R. Schreiber, Neuropsychopharmacology. 30, 2169 (2005).
78. W. D. Hirst, T. O. Stean, D. C. Rogers, D. Sunter, P. Pugh, S.F. Moss, et al. Eur. J. Pharmacol. 553, 109 (2006).
79. L. E. Schechter, Q. Lin, D. L. Smith, G. Zhang, Q. Shan, B. Platt, et al. Neuropsychopharmacology. 33, 1323 (2008).
80. C. Riemer, E. Borroni, B. Levet-Trafit, J. R. Martin, S. Poli, R. H. Porter, et al. J. Med. Chem. 46, 1273 (2003).
81. R. Kohen, M. A. Metcalf, N. Khan, T. Druck, K. Huebner, J. E. Lachowicz, et al. J. Neurochem. 66, 47 (1996).
82. Y. W. Yu, S. J. Tsai, C. H. Lin, C. P. Hsu, K. H. Yang and C. J. Hong, Neuroreport. 10, 1231 (1999).
83. G. A. Higgins, M. Enderlin, M. Haman and P.J. Fletcher, Psychopharmacology (Berl). 170, 309 (2003).
84. C. Miijana, M. Baviera, R. W. Invernizzi and C. Balducci, Neuropsychopharmacology. 29, 1637 (2004).
85. V. Boulougouris and T. W. Robbins, J. Neurosci. 30, 930 (2010).